About Orphic Pharma
Orphic Pharma is a Healthcare company. Manufacturing and exporting pharmaceutical medicines and drugs with a focus on quality and public health. Its Indian entity Orphic Pharma (India) Limited reported revenue of ₹3.12 Cr. Orphic Pharma offers products and services including Tablets and Capsules. Its focus areas include Public Health, Disease Prevention, Malaria and Dengue Initiatives and Pharmaceuticals.
Company details
Orphic Pharma (India) Ltd. is recognized for its role in manufacturing and exporting a comprehensive range of pharmaceutical medicines and drugs, with operations initiated in 2003. Quality is emphasized through ISO 9001-2008 certification, ensuring high standards in production. Products such as tablets, capsules, syrups, and powders are developed, while articles on the website address critical public health concerns like Malaria and Dengue, promoting habitat eradication measures. The company is situated in Vadodara, Gujarat, India, and engages in export activities to support global distribution efforts. This focus underscores its commitment to reliable pharmaceutical solutions.
- SectorsHealthcare
- Email••••••••
- Legal Name Orphic Pharma (India) Ltd
- Date of Incorporation 27 May, 2003
- Jurisdiction Vadodara, Gujarat, India
- Indian entity revenue₹3.12 Cr
FY 2025 · +33% YoY
- Indian entity net profit₹4.7 Lakh
FY 2025 · 2% margin
- Indian entity EBITDA₹9.2 Lakh
FY 2025 · 3% margin
Associated legal entities of Orphic Pharma
Orphic Pharma operates through Orphic Pharma (India) Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Orphic Pharma (India) Limited CIN U24239GJ2003PLC042431 | Active | 27 May 2003 | Vadodara, Gujarat | ₹3.1 Cr | 8 | View details |
Products & Services of Orphic Pharma
Orphic Pharma offers a comprehensive portfolio of products and services, including Tablets and Capsules.
Tablets such as Amic-DT are manufactured for medicinal purposes in the pharmaceutical sector.
Capsules like Amic-XL are produced for health treatments and distribution.
Board of directors of Orphic Pharma (India) Limited (Orphic Pharma)
Orphic Pharma (India) Limited is the primary company behind Orphic Pharma. The board of Orphic Pharma (India) Limited currently have 8 directors; the longest-serving is Patel Vinodkumar Babarbhai, appointed in 2003. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Patel Vinodkumar Babarbhai DIN 02357214 | Director | 27 May 2003 | 23 yrs 5 mo | Orphic Pharma (India) Limited |
| Sunita Agrawal DIN 01970895 | Director | 27 May 2003 | 23 yrs 5 mo | Orphic Pharma (India) Limited |
| Mansukhlal Ranchhod Govani DIN 01577959 | Director | 27 May 2003 | 23 yrs 5 mo | Orphic Pharma (India) Limited |
| Girish Chandra Agrawal DIN 01577983 | Director | 27 May 2003 | 23 yrs 5 mo | Orphic Pharma (India) Limited |
| Arpit Agrawal DIN 01578000 | Director | 21 Nov 2005 | 20 yrs 11 mo | Orphic Pharma (India) Limited |
| Vinodbhai Ranchhodbhai Govani DIN 03222005 | Director | 30 Aug 2010 | 16 yrs 1 mo | Orphic Pharma (India) Limited |
| Bharatbhai Mansukhbhai Kalavadiya DIN 07411992 | Director | 21 Jan 2016 | 10 yrs 9 mo | Orphic Pharma (India) Limited |
| Kamal Khairatilal Batra DIN 09765111 | Director | 01 Oct 2022 | 4 yrs | Orphic Pharma (India) Limited |
Financials of Orphic Pharma
Figures of Orphic Pharma (India) Limited, the primary company behind Orphic Pharma, for FY 2025. Revenue was ₹3.12 Cr (+33% year on year). Net profit was ₹4.7 Lakh (2% margin). EBITDA was ₹9.2 Lakh (3% margin). Revenue has grown at a compounded annual rate of +14% over three years and +10% over five years.
- ₹3.12 CrRevenue · FY 2025 · +33% YoY
- ₹4.7 LakhNet profit · 2% margin
- ₹9.2 LakhEBITDA · 3% margin
- ₹38.3 LakhPaid-up capital
- +14%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Orphic Pharma (India) Limited are on its company page.
Detailed financial statements for Orphic Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Orphic Pharma
The primary company behind Orphic Pharma, Orphic Pharma (India) Limited, reported revenue of ₹3.12 Cr for FY 2025, up 33% year on year.
Orphic Pharma (India) Ltd. is recognized for its role in manufacturing and exporting a comprehensive range of pharmaceutical medicines and drugs, with operations initiated in 2003. Quality is emphasized through ISO 9001-2008 certification, ensuring high standards in production. Products such as tablets, capsules, syrups, and powders are developed, while articles on the website address critical public health concerns like Malaria and Dengue, promoting habitat eradication measures. The company is situated in Vadodara, Gujarat, India, and engages in export activities to support global distribution efforts. This focus underscores its commitment to reliable pharmaceutical solutions.
Orphic Pharma offers Tablets and Capsules.
Orphic Pharma operates through Orphic Pharma (India) Limited.
The legal entities of Orphic Pharma currently have 8 directors, including Patel Vinodkumar Babarbhai, Sunita Agrawal, Arpit Agrawal and others.